Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

To push or to pull? In a post-COVID world, supporting and incentivizing antimicrobial drug development must become a governmental priority

Tools
- Tools
+ Tools

Cama, J., Leszczynski, R., Tang, P. K., Khalid, A., Lok, V., Dowson, Christopher G. and Ebata, A. (2021) To push or to pull? In a post-COVID world, supporting and incentivizing antimicrobial drug development must become a governmental priority. ACS Infectious Diseases . doi:10.1021/acsinfecdis.0c00681 (In Press)

[img]
Preview
PDF
WRAP-To-push-to-pull-post-COVID-world-supporting-antimicrobial-drug-2021.pdf - Accepted Version - Requires a PDF viewer.
Available under License Creative Commons Attribution 4.0.

Download (1282Kb) | Preview
Official URL: http://dx.doi.org/10.1021/acsinfecdis.0c00681

Request Changes to record.

Abstract

The COVID-19 pandemic has refocused attention worldwide on the dangers of infectious diseases, in terms of both global health and the effects on the world economy. Even in high income countries, health systems have been found wanting in dealing with the new infectious agent. However, the even greater long-term danger of antimicrobial resistance in pathogenic bacteria and fungi is still under-appreciated, especially among the general public. Although antimicrobial drug development faces significant scientific challenges, the gravest challenge at the moment appears to be economic, where the lack of a viable market has led to a collapse in drug development pipelines. There is therefore a critical need for governments across the world to further incentivize the development of antimicrobials. Most incentive strategies over the past decade have focused on so-called “push” incentives that bridge the costs of antimicrobial research and development, but these have been insufficient for reviving the pipeline. In this Perspective, we analyze the current incentive strategies in place for antimicrobial drug development, and focus on “pull” incentives, which instead aim to improve revenue generation and thereby resolve the antimicrobial market failure challenge. We further analyze these incentives in a broader “One Health” context and stress the importance of developing and enforcing strict protocols to ensure appropriate manufacturing practices and responsible use. Our analysis reiterates the importance of international cooperation, coordination across antimicrobial research, and sustained funding in tackling this significant global challenge. A failure to invest wisely and continuously to incentivize antimicrobial pipelines will have catastrophic consequences for global health and wellbeing in the years to come.

Item Type: Journal Article
Subjects: Q Science > QR Microbiology
R Medicine > RB Pathology
R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Science > Life Sciences (2010- )
Library of Congress Subject Headings (LCSH): Anti-infective agents, Anti-infective agents -- Development, Drug resistance in microorganisms , Drug resistance in microorganisms -- Prevention -- Government policy, Microorganisms -- Effect of drugs on
Journal or Publication Title: ACS Infectious Diseases
Publisher: American Chemical Society (ACS)
ISSN: 2373-8227
Official Date: 19 February 2021
Dates:
DateEvent
19 February 2021Published
28 October 2021Accepted
Date of first compliant deposit: 22 February 2021
DOI: 10.1021/acsinfecdis.0c00681
Status: Peer Reviewed
Publication Status: In Press
Access rights to Published version: Open Access
Copyright Holders: © 2021 American Chemical Society
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
204909/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100010269
BB/ S011269/1Global Challenges Research FundUNSPECIFIED
MR/S013598/1[MRC] Medical Research Councilhttp://dx.doi.org/10.13039/501100000265

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us